BUSINESS SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Product Revenues [Table Text Block]

The composition of total revenues was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2016		2015		2016		2015
Net product sales	$	4,432	$	3,572	$	8,396	$	6,631
Alliance revenues	418		552		827		1,507
Other revenues	21		39		39		66
Total Revenues	$	4,871	$	4,163	$	9,262	$	8,204

Product revenues were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2016		2015		2016		2015
Oncology
Empliciti (elotuzumab)	$	34	$	—	$	62	$	—
Erbitux* (cetuximab)	—		169		—		334
Opdivo (nivolumab)	840		122		1,544		162
Sprycel (dasatinib)	451		405		858		780
Yervoy (ipilimumab)	241		296		504		621
Cardiovascular
Eliquis (apixaban)	777		437		1,511		792
Immunoscience
Orencia (abatacept)	593		461		1,068		861
Virology
Baraclude (entecavir)	299		343		590		683
Hepatitis C Franchise	546		479		973		743
Reyataz (atazanavir sulfate) Franchise	247		303		468		597
Sustiva (efavirenz) Franchise	271		317		544		607
Neuroscience
Abilify* (aripiprazole)	35		107		68		661
Mature Products and All Other	537		724		1,072		1,363
Total Revenues	$	4,871	$	4,163	$	9,262	$	8,204

* Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q.